A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies

Sarah P. Blagden, T.R. Jeffry Evans, Pavlina Spiliopoulou et al.|Annals of Oncology|2018

Cited by 2